Search results for " live"

showing 10 items of 1548 documents

Hyperuricemia in non-alcoholic fatty liver disease: authors’ reply

2011

medicine.medical_specialtyHepatologybusiness.industryFatty liverGastroenterologyNon alcoholicDiseasemedicine.diseaseGastroenterologyInternal medicinemedicinePharmacology (medical)HyperuricemiabusinessAlimentary Pharmacology & Therapeutics
researchProduct

Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease

2011

SUMMARY Background Hyperuricemia has been associated with metabolic disorders. In this line recent studies observed an independent link between higher uric acid serum levels and clinical diagnosis of non-alcoholic fatty liver disease (NAFLD). Mean uric acid serum level was 5.75 mg ⁄ dL, and about 20% of patients had hyperuricemia, that was independently associated with younger age (OR 0.951, 95% CI 0.918-0.984, P = 0.004), lobular inflammation (OR 2.144, 95% CI 1.055-4.357, P = 0.03) and steatosis grade (OR 1.859, 95% CI 1.078-3.205, P = 0.02), by multivariate logistic regression analysis. Female gender (OR 2.656, 95% CI 1.190-5.928, P = 0.01), higher HOMA index (OR 1.219, 95% CI 1.043- 1.4…

medicine.medical_specialtyHepatologybusiness.industryFatty liverGastroenterologyNon alcoholicDiseasemedicine.diseaseLogistic regressionGastroenterologyEndocrinologyInternal medicineMedicinePharmacology (medical)In patientHyperuricemiaLiver damageSteatosisbusinessAlimentary Pharmacology & Therapeutics
researchProduct

P1013 : Chronic intermittent hypoxia is associated with liver damage and atherosclerosis in patients with non-alcoholic fatty liver disease

2015

all the steatosis grades, except S2 vs S3. The diagnostic performances of CAP in quantifying each steatosis grade was: for S ≥1 AUC=0.813 (cutoff 260dB/m, Se = 64.84%, Sp =87.27%, PPV=80.8%, NPV=75%, +LR =5.09, −LR =0.40, DA=76.11%); for S ≥2 AUC=0.822 (cutoff 285dB/m, Se = 69.70%, Sp =85.12%, PPV=47.9%, NPV=93.5%, +LR =4.68, −LR =0.36, DA=82.08%); for S ≥3 AUC=0.838 (cutoff 294dB/m, Se =83.33%, Sp =82.54%, PPV=23.3%, NPV=98.7%, +LR =4.77, −LR =0.20, DA=81.59%). AUCs calculated between two steatosis grades only were: 0.772 (for S0 vs S1), 0.874 (S0 vs S2), 0.904 (S0 vs S3), 0.659 (S1 vs S2), 0.777 (S1 vs S3), and 0.665 (S2 vs S3) respectively. Conclusions: Maximal diagnostic accuracy could …

medicine.medical_specialtyHepatologybusiness.industryFatty liverNon alcoholicDiseasemedicine.diseaseGastroenterologyInternal medicinemedicineCutoffChronic intermittent hypoxiaIn patientLiver damageSteatosisbusinessJournal of Hepatology
researchProduct

Letter: coronary atherosclerosis in patients with significant hepatic fibrosis in non‐alcoholic fatty liver disease—the role for non‐invasive testing

2021

medicine.medical_specialtyHepatologybusiness.industryFatty liverNon invasiveGastroenterologyNon alcoholicDiseasemedicine.diseaseGastroenterologyText miningInternal medicinemedicinePharmacology (medical)In patientbusinessHepatic fibrosisCoronary atherosclerosisAlimentary Pharmacology & Therapeutics
researchProduct

Assessment by Fibroscan of fibrosis in nonalcoholic fatty liver disease: XL versus M probe?

2012

--

medicine.medical_specialtyHepatologybusiness.industryFibrosisInternal medicineNAFLD FIBROSIS FIBROSCANNonalcoholic fatty liver diseasemedicinemedicine.diseasebusinessGastroenterologyLiver pathologyHepatology
researchProduct

Screening for celiac disease in patients with chronic liver disease

2003

Dear Sir:We read with interest the paper of Kaukinen et al. reporting anelevated frequency of celiac disease (CD) (4.3%) in patients with previousliver transplantation due to severe hepatic dysfunction.1However, wewould like to report our experience of the serologic assays for CDdiagnosis in patients with chronic liver disease and comment on thescreening methods for CD used in that study. Between January andOctober 2001, we studied 96 consecutive subjects (65 male, 31 female,age range 18–87 years, median 42) with chronic hypertransaminasemiawho were attending for thefirst time the outpatients clinic for liverdisease at the Internal Medicine Division of the University Hospital ofPalermo. All…

medicine.medical_specialtyHepatologybusiness.industryGastroenterologyMEDLINEDiseaseChronic liver diseasemedicine.diseaseGastroenterologyChronic diseaseInternal medicinemedicineScreening celiac disease chronic liver diseaseIn patientbusiness
researchProduct

FNDC5 rs3480 A>G polymorphism disentangles steatosis from fibrosis severity in patients with nonalcoholic fatty liver disease

2016

S. Petta1, L. Valenti2, R.M. Pipitone1, P. Dongiovanni2, C. Camma1, A.L. Fracanzani2, V. Di Marco1, M. Milano2, S. Grimaudo1, S. Fargion2, A. Craxi1 1 Section of Gastroenterology, Di.Bi.M.I.S., University of Palermo, Palermo, Italy 2 Department of Pathophysiology and Transplantation, Universita degli Studi, Internal Medicine, Fondazione Ca’ Granda IRCCS Ospedale Maggiore Policlinico, Milano, Italy

medicine.medical_specialtyHepatologybusiness.industryGastroenterologymedicine.diseaseGastroenterologyFNDC5TransplantationFibrosisInternal medicineNonalcoholic fatty liver diseaseMedicineIn patientSteatosisbusinessDigestive and Liver Disease
researchProduct

Nonalcoholic Fatty Liver Disease Increases the Risk of Anxiety and Depression.

2020

Nonalcoholic fatty liver disease (NAFLD), depression, and anxiety disorders are frequent diseases, and data on mutual influence are inconsistent. The aim of this study was to explore the incidence of depression and anxiety in a large primary care cohort in Germany and to study the impact of NAFLD over a 10‐year time frame. Patients with NAFLD diagnosed between 2010 and 2015 were matched to a cohort without NAFLD controlling for age, sex, physician, index year, and Charlson comorbidity index. The primary outcome of the study was the incidence of depression, anxiety, and first prescription of antidepressant drugs. We compared 19,871 patients with NAFLD to 19,871 matched controls. Within 10 ye…

medicine.medical_specialtyHepatologybusiness.industryIncidence (epidemiology)Hazard ratioConfoundingOriginal Articlesmedicine.diseaseInternal medicineNonalcoholic fatty liver diseaseCohortMedicineAnxietylcsh:Diseases of the digestive system. GastroenterologyOriginal Articlelcsh:RC799-869medicine.symptomRisk factorbusinessDepression (differential diagnoses)Hepatology communications
researchProduct

OC.03.2 THE PRESENCE OF WHITE MATTER LESIONS IS ASSOCIATED WITH THE HISTOLOGICAL SEVERITY OF NON-ALCOHOLIC FATTY LIVER DISEASE

2016

medicine.medical_specialtyHepatologybusiness.industryInternal medicineFatty liverGastroenterologyMedicineNon alcoholicDiseasebusinessmedicine.diseaseGastroenterologyHyperintensityDigestive and Liver Disease
researchProduct

Early menopausal status is associated with the severity of liver fibrosis in Italian patients with non-alcoholic fatty liver disease

2014

medicine.medical_specialtyHepatologybusiness.industrySettore MED/12 - GASTROENTEROLOGIALiver fibrosisFatty liverGastroenterologyNon alcoholicDiseasemedicine.diseaseGastroenterologyInternal medicinemedicinebusinessDigestive and Liver Disease
researchProduct